MEDICUS PHARMA LTD. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
MEDICUS PHARMA LTD. (MDCX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$5.32 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-25
- MEDICUS PHARMA LTD. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$5.32M.
- MEDICUS PHARMA LTD. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$2.96M.
- MEDICUS PHARMA LTD. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$1.41M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$5.32M 10-K · filed 2026-03-25 |
| 2024-12-31 | -$2.96M 10-K · filed 2026-03-25 |
| 2023-12-31 | -$1.41M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |